LSE - Small Logo
LSE - Small Logo

Dipa Patel20

January 30th, 2018

Cutting Edge Issues in Development: Using Markets for Development? The Potential of Advanced Market Commitments

0 comments

Estimated reading time: 5 minutes

Dipa Patel20

January 30th, 2018

Cutting Edge Issues in Development: Using Markets for Development? The Potential of Advanced Market Commitments

0 comments

Estimated reading time: 5 minutes

Graduate student, Shahrukh Wani, reflects on a Cutting Edge in Development talk by guest lecturer Owen Barder, Vice President at the Center for Global Development, about understanding system incentives and markets for development. 

Markets are good for a lot of things. They have an irrefutable ability to cater to our demands, how seemingly ridiculous our demands might be. Think about silly putty. If enough people want it, they will get it. But there is a catch. You must be able to afford it. You can desire as much silly putty you want but if you can’t afford it or there isn’t demand from enough people to bring the per unit cost down for you to afford it, the market won’t deliver.

The same limitation of market translates to a bigger problem for development practitioners. This means that if there is a demand for an essential product such as a vaccine from the cash-strapped developing countries, but there isn’t demand for the same product from wealthier potential customers in the developed countries. The market won’t deliver.

This means that there is a deficit of incentives for the market to provide a product to people who can’t afford it. In the case of vaccine’s, the challenge seems to be startling. The development of vaccines could save millions of lives, but pharmaceutical companies don’t have the incentive to put their money in research of these vaccines when there is little economic return.

Owen Barder, Vice President at the Center for Global Development, speaks to LSE graduate students about understanding system incentives and markets

In a recent guest lecture at the London School of Economics, economist Owen Barder asked students to guess how much does the world spend seeking a cure for malaria in comparison to the global spending to cure male baldness.

The answer, which most of us guessed correctly, is about a tenth.

The reason is simple, pharmaceutical companies can’t offset the cost of developing malaria vaccine to the consumers unlike whatever remedy it develops for male baldness. “So, these companies are already taking the risk for rich countries who can pay more, but not for poor states who may not,” Owen says.

The solution? Manipulating the markets so the vaccines demanded by lower-income countries work in a similar manner that those demanded by richer countries. This intuition made the basses of a 2005 report by the Centre for Global Development, which Owen co-authored.

“Barely 10% of global R&D is devoted to diseases that affect 90% of the world’s population,” the report notes.

The report proposed that the global donors to make an “advance market commitment (or AMC)” to pay for a certain number of successful pneumococcal vaccines, in turn offsetting research and development costs which the pharmaceutical companies would bear. “If it (vaccine) doesn’t work, it doesn’t cost us (the donors) anything.”

The idea is strikingly simple. Instead of spending the money on sponsoring research for the vaccine, donors enter into a legal agreement with pharmaceutical companies for purchasing a number of vaccine in advance at a price high enough to incentivize companies to invest in research, in turn subsidising developing countries to save lives.

When Owen and his colleagues told donors about the idea, the response was similar “it is such a good idea that somebody might have already done it.”

The concept was luring enough that within months the G7 Finance Ministers backed the proposal in a conference in London. In 2009, this led to five countries, along with the Gates Foundation, to commit to $1.5 billion for a vaccine for pneumococcal diseases which, in 2005, had caused approximately 1.6 million deaths, almost exclusively in developing countries.

By 2010, GlaxoSmithKline and Pfizer had announced a development of a pneumococcal vaccine under the AMC program. According to estimates, this vaccine would have averted approximately 1.5 million deaths among children by 2020.

Despite this success, the concept hasn’t been replicated for other diseases. Owen admits that it is difficult in binding donors for a long-term commitment to buy these vaccines years from now. Owen admits that negotiating a legally binding contract was critical in the case of pneumococcal vaccine.

Another challenge which Owen notes is the “distant lack of enthusiasm from disease researchers from bringing the drug companies in.” Referring to researchers who rely on grants to explore vaccines for diseases prevalent in developing countries.

“You come on television and say that you will spend 1.5 billion of the taxpayer’s money, but the leading expert on the disease disagrees with you publically.”

AMC’s provides evidence that incentivizing the market can work for solving key development challenges. But like most good ideas, it needs a lot of leg work, and even more, vibrant intellectual discourse among development thinkers.

Can markets work for development? AMCs show that they can. As long as we remember that it’s all about the incentives.


Shahrukh Wani (@ShahrukhWani) is a graduate student at the LSE from Pakistan. He has written about development issues for, among others, the Guardian, and c0-hosts a podcast “The World Isn’t Flat”. 

The views expressed in this post are those of the author and in no way reflect those of the International Development LSE blog or the London School of Economics and Political Science.

About the author

Dipa Patel20

Posted In: Events | Featured | Student Experience | Topical and Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

RSS Justice and Security Research Programme

  • JSRP and the future
    The JSRP drew to a close in 2017 but many of the researchers and partners involved in the programme continue to work on the issues and theories developed during the lifetime of the programme. Tim Allen now directs the Firoz Lalji Centre for Africa (FLCA) at LSE where many of the JSRP research team working […]
  • Life after the LRA
    The JSRP reached the end of its grant in spring 2017 but several outputs from the programme are scheduled for publication in the coming months. The most recent of these is a new journal article from Holly Porter and Letha Victor drawing on their extensive research with JSRP in the Acholi region of northern Uganda.  The […]

RSS LSE’s engagement with South Asia

  • Growing up in a Digital World: Vulnerabilities of Children in post-Pandemic India
    The closing down of schools during the Covid-19 pandemic meant a complete reliance on online teaching for students to ensure that formal education remained as little disrupted as possible. Simultaneously, remaining at home for extended periods of time meant that children were spending more and more time online, for socialisation and entertainment. This has inevitably […]
  • ‘Haqiqi’ (True) Development: Communities Coming Together for Polio Immunisation in Pakistan
    Pakistan is one of only two countries in the world (along with Afghanistan) which is yet to eradicate the highly infectious Wild Polio Virus (WPV1). In this post, Tahira Ali, Savaila Hunzai and Zahra Rao outline how locally-rooted, empathetic and culturally sensitive practices can help overcome barriers, and help increase the percentage of polio vaccination […]